approval · primary record
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
FDA · NDA · 2026-07-31
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-07-31 |
| Approval events | 1 |
| Brand | PLUVICTO |
| Sponsor | NOVARTIS |
| Route | INTRAVENOUS |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-07-31 | FDA | NDA | PLUVICTO | NOVARTIS | INTRAVENOUS |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:11.491Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:lutetium-lu-177-vipivotide-tetraxetan
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lutetium Lu-177 Vipivotide Tetraxetan · compound